1. 1. Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer epidemiology, biomarkers & prevention, 28(10): 1563-1579. [
DOI:10.1158/1055-9965.EPI-19-0221] [
PMID] [
]
2. Liu H, Xie R, Dai Q, et al. (2023) Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. Scientific Reports, 13(1): 7161. [
DOI:10.1038/s41598-023-34426-y] [
PMID] [
]
3. Liu H, Tang T (2023) MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Scientific Reports, 13(1): 19055. [
DOI:10.1038/s41598-023-45774-0] [
PMID] [
]
4. Ko EC, Raben D, Formenti SC (2018) The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clinical Cancer Research, 24(23): 5792-5806. [
DOI:10.1158/1078-0432.CCR-17-3620] [
PMID]
5. Jacobsen MM, Silverstein SC, Quinn M, et al. (2017) Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung cancer, 112: 156-164. [
DOI:10.1016/j.lungcan.2017.08.011] [
PMID]
6. Chang Y, Xiao F, Quan H, et al. (2020) Evaluation of OAR dose sparing and plan robustness of beam-specific PTV in lung cancer IMRT treatment. Radiation Oncology, 15(1): 1-12. [
DOI:10.1186/s13014-020-01686-1] [
PMID] [
]
7. Fornacon-Wood I, Chan C, Bayman N, et al. (2022) Impact of introducing intensity modulated radiotherapy on curative intent radiotherapy and survival for lung cancer. Frontiers in Oncology, 12: 2432. [
DOI:10.3389/fonc.2022.835844] [
PMID] [
]
8. Chen N-B, Li Q-W, Zhu Z-F, et al. (2020) Developing and validating an integrated gross tumor volume (GTV)-TNM stratification system for supplementing unresectable locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiation Oncology, 15: 1-12. [
DOI:10.1186/s13014-020-01704-2] [
PMID] [
]
9. Zhang X, Rong Y, Morrill S, et al. (2018) Robust optimization in lung treatment plans accounting for geometric uncertainty. Journal of applied clinical medical physics, 19(3): 19-26. [
DOI:10.1002/acm2.12291] [
PMID] [
]
10. Zhao J, Zhang W, Er P, et al. (2020) Concurrent or sequential chemoradiotherapy after 3-4 cycles induction chemotherapy for ls-sclc with bulky tumor. Journal of Cancer, 11(17): 4957. [
DOI:10.7150/jca.41136] [
PMID] [
]
11. Li J, Fu X, Fu J (2017) Exhaled Nitric oxide is useful in symptomatic radioactive pneumonia: a retrospective study. Mediators of Inflammation. [
DOI:10.1155/2017/5840813] [
PMID] [
]
12. Chai G, Yin Y, Zhou X, et al. (2020) Pulmonary oligometastases treated by stereotactic body radiation therapy (SBRT): A single institution's experience. Translational Lung Cancer Research, 9(4): 1496. [
DOI:10.21037/tlcr-20-867] [
PMID] [
]
13. Kandathil A, Kay FU, Butt YM, et al. (2018) Role of FDG PET/CT in the eighth edition of TNM staging of non-small cell lung cancer. Radiographics, 38(7): 2134-2149. [
DOI:10.1148/rg.2018180060] [
PMID]
14. Zhao M, Ma Y, Yang B, et al. (2016) A meta-analysis to evaluate the diagnostic value of dual-time-point F-fluorodeoxyglucose positron emission tomography/computed tomography for diagnosis of pulmonary nodules. Journal of cancer research and therapeutics, 12(Special 3): C304-C308. [
DOI:10.4103/0973-1482.200742] [
PMID]
15. Colletti PM (2020) Reverse phase encoding-corrected DWI Improves MRI for PET/MRI of lung cancer. Radiological Society of North America, 701-702. [
DOI:10.1148/radiol.2020200155] [
PMID]
16. Shen S, Zhang S, Liu P, et al. (2020) Potential role of microRNAs in the treatment and diagnosis of cervical cancer. Cancer Genet, 248-249: 25-30. [
DOI:10.1016/j.cancergen.2020.09.003] [
PMID]
17. Bezjak A, Paulus R, Gaspar LE, et al. (2019) Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG oncology/RTOG 0813 trial. Journal of Clinical Oncology, 37(15): 1316. [
DOI:10.1200/JCO.18.00622] [
PMID] [
]
18. Liang JA, Tu CY, Hsia TC, et al. (2020) Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy. Thoracic cancer, 11(9): 2639-2649. [
DOI:10.1111/1759-7714.13596] [
PMID] [
]
19. Yan WL, Lv JS, Guan ZY, et al. (2017) Impact of target area selection in 125 I odine seed brachytherapy on locoregional recurrence in patients with non‐small cell lung cancer. Thoracic Cancer, 8(3): 147-152. [
DOI:10.1111/1759-7714.12415] [
PMID] [
]
20. Abuodeh Y, Naghavi AO, Echevarria M, et al. (2018) Quantitatively excessive normal tissue toxicity and poor target coverage in postoperative lung cancer radiotherapy meta-analysis. Clinical Lung Cancer, 19(1): e123-e30. [
DOI:10.1016/j.cllc.2017.06.009] [
PMID]
21. Shen T, Sheng L, Chen Y, et al. (2020) High incidence of radiation pneumonitis in lung cancer patients with chronic silicosis treated with radiotherapy. Journal of Radiation Research, 61(1): 117-122. [
DOI:10.1093/jrr/rrz084] [
PMID] [
]
22. Appel S, Bar J, Ben-Nun A, et al. (2019) Comparative effectiveness of intensity modulated radiation therapy to 3-dimensional conformal radiation in locally advanced lung cancer: pathological and clinical outcomes. The British Journal of Radiology, 92(1097): 20180960. [
DOI:10.1259/bjr.20180960] [
PMID] [
]
23. Zurstrassen CE, Tyng CJ, Guimarães MD, et al. (2020) Functional and metabolic imaging in transthoracic biopsies guided by computed tomography. European Radiology, 30: 2041-2048. [
DOI:10.1007/s00330-019-06591-0] [
PMID]
